Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Dong Dong, Baojian Wu, Diana Chow & Ming Hu. (2012) Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metabolism Reviews 44:2, pages 192-208.
Read now
Read now
Dong Dong & Baojian Wu. (2012) Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metabolism Reviews 44:1, pages 1-17.
Read now
Read now
Nitish Kumar Mishra. (2011) Computational modeling of P450s for toxicity prediction. Expert Opinion on Drug Metabolism & Toxicology 7:10, pages 1211-1231.
Read now
Read now
Bo Wang, Li-Ping Yang, Xiao-Zhuang Zhang, Shui-Qing Huang, Mark Bartlam & Shu-Feng Zhou. (2009) New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metabolism Reviews 41:4, pages 573-643.
Read now
Read now
A. D. Costache, D. Trawick, D. Bohl & D. S. Sem. (2007) AmineDB: Large scale docking of amines with CYP2D6 and scoring for druglike properties—towards defining the scope of the chemical defense against foreign amines in humans. Xenobiotica 37:3, pages 221-245.
Read now
Read now
Sean Ekins, Sergey Andreyev, Andy Ryabov, Eugene Kirillov, Eugene A Rakhmatulin, Andrej Bugrim & Tatiana Nikolskaya. (2005) Computational prediction of human drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 1:2, pages 303-324.
Read now
Read now
David F. V. Lewis, Sandeep Modi & Maurice Dickins. (2002) Structure–activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metabolism Reviews 34:1-2, pages 69-82.
Read now
Read now
David F. V. Lewis. (2002) Molecular modeling of human cytochrome P450–substrate interactions. Drug Metabolism Reviews 34:1-2, pages 55-67.
Read now
Read now
David F.V. Lewis & Maurice Dickins. (2001) Quantitative Structure-Activity Relationships (QSARs) Within Series of Inhibitors for Mammalian Cytochromes P450 (CYPs). Journal of Enzyme Inhibition 16:4, pages 321-330.
Read now
Read now
S. A. Roberts. (2001) High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31:8-9, pages 557-589.
Read now
Read now
Articles from other publishers (62)
Barbara M. A. van Vugt-Lussenburg, Liliana Capinha, Jelle Reinen, Martijn Rooseboom, Michel Kranendonk, Rob C. A. Onderwater & Paul Jennings. (2022)
“
Commandeuring
” Xenobiotic Metabolism: Advances in Understanding Xenobiotic Metabolism
. Chemical Research in Toxicology 35:7, pages 1184-1201.
Crossref
Crossref
Usman Ali Ashfaq, Farah Shahid & Samman Munir. 2022. Biochemistry of Drug Metabolizing Enzymes. Biochemistry of Drug Metabolizing Enzymes
29
72
.
Gudrun Hefner, Jan Wolff, Martina Hahn, Christoph Hiemke, Sermin Toto, Sibylle C. Roll, Thomas Messer & Ansgar Klimke. (2020) Prevalence and sort of pharmacokinetic drug–drug interactions in hospitalized psychiatric patients. Journal of Neural Transmission 127:8, pages 1185-1198.
Crossref
Crossref
A.A. Heller, S.Y. Lockwood, T.M. Janes & D.M. Spence. (2018) Technologies for Measuring Pharmacokinetic Profiles. Annual Review of Analytical Chemistry 11:1, pages 79-100.
Crossref
Crossref
Gudrun Hefner, Stefan Unterecker, Mohamed E. E. Shams, Margarete Wolf, Tanja Falter, Ekkehard Haen & Christoph Hiemke. (2015) Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. Journal of Neural Transmission 122:11, pages 1609-1617.
Crossref
Crossref
F. Peter Guengerich. 2015. Cytochrome P450. Cytochrome P450
523
785
.
Alexander V. LyubimovBill Gurley, Kim E. Fifer & Zöe Gardner. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
79
.
Patrick R. Verhoest, Aarti Sawant Basak, Vinod Parikh, Matthew Hayward, Gregory W. Kauffman, Vanessa Paradis, Stanton F. McHardy, Stafford McLean, Sarah Grimwood, Anne W. Schmidt, Michelle Vanase-Frawley, Jodi Freeman, Jeffrey Van Deusen, Loretta Cox, Diane Wong & Spiros Liras. (2011)
Design and Discovery of a Selective Small Molecule κ Opioid Antagonist (2-Methyl-
N
-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)
. Journal of Medicinal Chemistry 54:16, pages 5868-5877.
Crossref
Crossref
Stanton F. McHardy, Steven D. Heck, Sara Guediche, Monica Kalman, Martin P. Allen, Meihua Tu, Dianne K. Bryce, Anne W. Schmidt, Michelle Vanase-Frawley, Ernesto Callegari, Shawn Doran, Nicholas J. Grahame, Stafford McLean & Spiros Liras. (2011) Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence. MedChemComm 2:10, pages 1001.
Crossref
Crossref
Britta Bonn, Collen M. Masimirembwa & Neal CastagnoliJr.Jr.. (2010) Exploration of Catalytic Properties of CYP2D6 and CYP3A4 Through Metabolic Studies of Levorphanol and Levallorphan. Drug Metabolism and Disposition 38:1, pages 187-199.
Crossref
Crossref
Marcel J. de Groot, Florian Wakenhut, Gavin Whitlock & Ruth Hyland. (2009) Understanding CYP2D6 interactions. Drug Discovery Today 14:19-20, pages 964-972.
Crossref
Crossref
Youbin Tu, Rahul Deshmukh, Meena Sivaneri & Grazyna D. Szklarz. (2008) Application of Molecular Modeling for Prediction of Substrate Specificity in Cytochrome P450 1A2 Mutants. Drug Metabolism and Disposition 36:11, pages 2371-2380.
Crossref
Crossref
Britta Bonn, Collen M. Masimirembwa, Yasmin Aristei & Ismael Zamora. (2008)
The Molecular Basis of CYP2D6-Mediated
N
-Dealkylation: Balance between Metabolic Clearance Routes and Enzyme Inhibition
. Drug Metabolism and Disposition 36:11, pages 2199-2210.
Crossref
Crossref
Jihoon Jung, Nam Doo Kim, Su Yeon Kim, Inhee Choi, Kwang-Hwi Cho, Won Seok Oh, Doo Nam Kim & Kyoung Tai No. (2008) Regioselectivity Prediction of CYP1A2-Mediated Phase I Metabolism. Journal of Chemical Information and Modeling 48:5, pages 1074-1080.
Crossref
Crossref
J‐D Maréchal, C A Kemp, G C K Roberts, M J I Paine, C R Wolf & M J Sutcliffe. (2009) Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6‐drug interactions. British Journal of Pharmacology 153:S1.
Crossref
Crossref
Larry J. Jolivette & Sean Ekins. 2007.
131
176
.
R. L. Haining. 2007. Handbook of Neurochemistry and Molecular Neurobiology. Handbook of Neurochemistry and Molecular Neurobiology
43
91
.
P. Crivori & I. Poggesi. (2006) Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. European Journal of Medicinal Chemistry 41:7, pages 795-808.
Crossref
Crossref
Peter Hlavica. (2006) Functional interaction of nitrogenous organic bases with cytochrome P450: A critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1764:4, pages 645-670.
Crossref
Crossref
Paul Rowland, Frank E. Blaney, Martin G. Smyth, Jo J. Jones, Vaughan R. Leydon, Amanda K. Oxbrow, Ceri J. Lewis, Mike G. Tennant, Sandeep Modi, Drake S. Eggleston, Richard J. Chenery & Angela M. Bridges. (2006) Crystal Structure of Human Cytochrome P450 2D6. Journal of Biological Chemistry 281:11, pages 7614-7622.
Crossref
Crossref
Michael Murray. 2005. Modern Biopharmaceuticals. Modern Biopharmaceuticals
1603
1636
.
Takashi Kamachi, Naoki Kihara, Yoshihito Shiota & Kazunari Yoshizawa. (2005) Computational Exploration of the Catalytic Mechanism of Dopamine β-Monooxygenase: Modeling of Its Mononuclear Copper Active Sites. Inorganic Chemistry 44:12, pages 4226-4236.
Crossref
Crossref
Delphine Allorge, Didier Bréant, Jacky Harlow, Joey Chowdry, Jean-Marc Lo-Guidice, Dany Chevalier, Christelle Cauffiez, Michel Lhermitte, Frank E. Blaney, Geoffrey T. Tucker, Franck Broly & S. Wynne Ellis. (2005) Functional analysis of CYP2D6.31 variant: Homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins: Structure, Function, and Bioinformatics 59:2, pages 339-346.
Crossref
Crossref
Aiko Ebisawa, Masahiro Hiratsuka, Kanako Sakuyama, Yumiko Konno, Takamitsu Sasaki & Michinao Mizugaki. (2005) Two Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2D6 Gene in Japanese Individuals. Drug Metabolism and Pharmacokinetics 20:4, pages 294-299.
Crossref
Crossref
Carol A. Kemp, Jean-Didier Maréchal & Michael J. Sutcliffe. (2005) Progress in cytochrome P450 active site modeling. Archives of Biochemistry and Biophysics 433:2, pages 361-368.
Crossref
Crossref
F. Peter Guengerich. 2005. Cytochrome P450. Cytochrome P450
377
530
.
Huili Yao, Aurora D. Costache & Daniel S. Sem. (2004)
Chemical Proteomic Tool for Ligand Mapping of CYP Antitargets: An NMR-Compatible 3D QSAR Descriptor in the
Heme-Based Coordinate System
. Journal of Chemical Information and Computer Sciences 44:4, pages 1456-1465.
Crossref
Crossref
Rory P. Remmel, Brenda C. Crews, Kevin R. Kozak, Amit S. Kalgutkar & Lawrence J. Marnett. (2004) STUDIES ON THE METABOLISM OF THE NOVEL, SELECTIVE CYCLOOXYGENASE-2 INHIBITOR INDOMETHACIN PHENETHYLAMIDE IN RAT, MOUSE, AND HUMAN LIVER MICROSOMES: IDENTIFICATION OF ACTIVE METABOLITES. Drug Metabolism and Disposition 32:1, pages 113-122.
Crossref
Crossref
Shahriar Haji-Momenian, Jayson M Rieger, Timothy L Macdonald & Milton L Brown. (2003) Comparative molecular field analysis and QSAR on substrates binding to cytochrome P450 2D6. Bioorganic & Medicinal Chemistry 11:24, pages 5545-5554.
Crossref
Crossref
Amit S. Kalgutkar, Sue Zhou, Odette A. Fahmi & Timothy J. Taylor. (2003)
Influence of Lipophilicity on the Interactions of
N-
Alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and Their Positively Charged
N-
Alkyl-4-phenylpyridinium Metabolites with Cytochrome P450 2D6
. Drug Metabolism and Disposition 31:5, pages 596-605.
Crossref
Crossref
Peter K Rogan, Stan Svojanovsky & J Steven Leeder. (2003) Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 13:4, pages 207-218.
Crossref
Crossref
David F. V. Lewis. (2003) Quantitative structure–activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. InflammoPharmacology 11:1, pages 43-73.
Crossref
Crossref
Mark J.I. Paine, Lesley A. McLaughlin, Jack U. Flanagan, Carol A. Kemp, Michael J. Sutcliffe, Gordon C.K. Roberts & C. Roland Wolf. (2003) Residues Glutamate 216 and Aspartate 301 Are Key Determinants of Substrate Specificity and Product Regioselectivity in Cytochrome P450 2D6. Journal of Biological Chemistry 278:6, pages 4021-4027.
Crossref
Crossref
Takahito Yamamoto, Naoko Hagima, Misako Fukasawa, Jun-ichi Yamaguchi, Masato Nakamura, Yoshiro Kohno, Kiyoshi Nagata & Yasushi Yamazoe. (2003) Metabolism of N,N-Dipropyl-2-[4-Methoxy-3-(2-Phenyl-Ethoxy)-Phenyl]-Ethyl-Amine-Monohydrochloride (NE-100), A Novel Sigma Ligand: Contribution of Cytochrome P450 Forms Involved in the Formation of Individual Metabolites in Human Liver and Small Intestine. Drug Metabolism and Pharmacokinetics 18:3, pages 173-185.
Crossref
Crossref
David F.V. Lewis, Maurice Dickins, Brian G. Lake & Peter S. Goldfarb. (2003) A MOLECULAR MODEL OF CYP2D6 CONSTRUCTED BY HOMOLOGY WITH THE CYP2C5 CRYSTALLOGRAPHIC TEMPLATE: INVESTIGATION OF ENZYME-SUBSTRATE INTERACTIONS. Drug Metabolism and Drug Interactions 19:3.
Crossref
Crossref
Jennifer Venhorst, Antonius M. ter Laak, Jan N. M. Commandeur, Yoshihiko Funae, Toyoko Hiroi & Nico P. E. Vermeulen. (2002) Homology Modeling of Rat and Human Cytochrome P450 2D (CYP2D) Isoforms and Computational Rationalization of Experimental Ligand-Binding Specificities. Journal of Medicinal Chemistry 46:1, pages 74-86.
Crossref
Crossref
Larry C. Wienkers & Michael A. Wynalda. (2002)
Multiple Cytochrome P450 Enzymes Responsible for the Oxidative Metabolism of the Substituted (
S
)-3-Phenylpiperidine, (
S
,
S
)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine Hydrochloride, in Human Liver Microsomes
. Drug Metabolism and Disposition 30:12, pages 1372-1377.
Crossref
Crossref
B. Rege, K. M. Carter, M. A. Sarkar, G. E. Kellogg & W. H. Soine. (2002) Irreversible Inhibition of CYP2D6 by (−)-Chloroephedrine, a Possible Impurity in Methamphetamine. Drug Metabolism and Disposition 30:12, pages 1337-1343.
Crossref
Crossref
Tomoko Shiraishi, Masakiyo Hosokawa, Kaoru Kobayashi, Hitoshi Tainaka, Yoshiyuki Yamaura, Miwo Taguchi & Kan Chiba. (2002)
Effects of G169R and P34S Substitutions Produced by Mutations of
CYP2D6*14
on the Functional Properties of CYP2D6 Expressed in V79 Cells
. Drug Metabolism and Disposition 30:11, pages 1201-1205.
Crossref
Crossref
Tashinga E Bapiro, Julia A Hasler, Marianne Ridderström & Collen M Masimirembwa. (2002) The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Biochemical Pharmacology 64:9, pages 1387-1398.
Crossref
Crossref
Stewart B. Kirton, Carol A. Kemp, Nicholas P. Tomkinson, Steven St.‐Gallay & Michael J. Sutcliffe. (2002) Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins: Structure, Function, and Bioinformatics 49:2, pages 216-231.
Crossref
Crossref
David F.V. Lewis. (2002) Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template. Journal of Inorganic Biochemistry 91:4, pages 502-514.
Crossref
Crossref
Darko Butina, Matthew D Segall & Katrina Frankcombe. (2002) Predicting ADME properties in silico: methods and models. Drug Discovery Today 7:11, pages S83-S88.
Crossref
Crossref
Stewart B Kirton, Carol A Baxter & Michael J Sutcliffe. (2002) Comparative modelling of cytochromes P450. Advanced Drug Delivery Reviews 54:3, pages 385-406.
Crossref
Crossref
D. F. V. Lewis. 2002. Pharmacokinetic Challenges in Drug Discovery. Pharmacokinetic Challenges in Drug Discovery
235
248
.
Daisuke Tsuzuki, Chie Takemi, Shigeo Yamamoto, Keietsu Tamagake, Susumu Imaoka, Yoshihiko Funae, Hiroyuki Kataoka, Sumio Shinoda & Shizuo Narimatsu. (2001) Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae. Pharmacogenetics 11:8, pages 709-718.
Crossref
Crossref
David Lewis. 2001. Guide to Cytochromes P450. Guide to Cytochromes P450
164
210
.
Agneta Wennerholm, Inger Johansson, Mats Hidestrand, Leif Bertilsson, Lars L. Gustafsson & Magnus Ingelman-Sundberg. (2001) Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11:5, pages 417-427.
Crossref
Crossref
David F?V Lewis. (2001) COMPACT: a structural approach to the modelling of cytochromes P450 and their interactions with xenobiotics. Journal of Chemical Technology & Biotechnology 76:3, pages 237-244.
Crossref
Crossref
D.F.V. Lewis, S. Modi & M. Dickins. (2001) Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochromes P450 Involved in Drug Metabolism. Drug Metabolism and Drug Interactions 18:3-4.
Crossref
Crossref
Shizuo NARIMATSU, Takayuki ARAI, Yasuhiro MASUBUCHI, Toshiharu HORIE, Masakiyo HOSOKAWA, Koichi UENO, Hiroyuki KATAOKA, Shigeo YAMAMOTO, Tsutomu ISHIKAWA & Arthur K. CHO. (2001) Inactivation of Rat Cytochrome P450 2D Enzyme by a Further Metabolite of 4-Hydroxypropranolol, the Major and Active Metabolite of Propranolol.. Biological and Pharmaceutical Bulletin 24:9, pages 988-994.
Crossref
Crossref
David F.V. Lewis. (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochemical Pharmacology 60:3, pages 293-306.
Crossref
Crossref
Shizuo Narimatsu, Naoko Kobayashi, Yasuhiro Masubuchi, Toshiharu Horie, Tomohito Kakegawa, Hiroshi Kobayashi, James P. Hardwick, Frank J. Gonzalez, Noriaki Shimada, Shigeru Ohmori, Mitsukazu Kitada, Kazuo Asaoka, Hiroyuki Kataoka, Shigeo Yamamoto & Testuo Satoh. (2000) Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes. Chemico-Biological Interactions 127:1, pages 73-90.
Crossref
Crossref
Ronald E. White. (2000) High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery. Annual Review of Pharmacology and Toxicology 40:1, pages 133-157.
Crossref
Crossref
David F.V. Lewis. (2000) Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 144:1-3, pages 197-203.
Crossref
Crossref
D.F.V. Lewis. (2000) Modelling Human Cytochromes P450 for Evaluating Drug Metabolism: An Update. Drug Metabolism and Drug Interactions 16:4.
Crossref
Crossref
Brian Cox, Andy T. Merritt, Alastair Binnie, Mary C. Donnelly, Tom H. Mander, Jane C. Denyer, Brian Evans, Darren V.S. Green, Jane A. Lewis, Martin J. Valler & Stephen P. Watson. 2000.
83
133
.
David F.V. Lewis, Brian G. Lake, Stephen G. George, Maurice Dickins, Peter J. Eddershaw, Michael H. Tarbit, Alan P. Beresford, Peter S. Goldfarb & F.Peter Guengerich. (1999) Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139:1-2, pages 53-79.
Crossref
Crossref
D.F.V. Lewis, P.J. Eddershaw, M. Dickins, M.H. Tarbit & P.S. Goldfarb. (1998) Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chemico-Biological Interactions 115:3, pages 175-199.
Crossref
Crossref
D.F.V. Lewis, E. Watson & B.G. Lake. (1998) Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutation Research/Reviews in Mutation Research 410:3, pages 245-270.
Crossref
Crossref
Michael H Tarbit & Judd Berman. (1998) High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Current Opinion in Chemical Biology 2:3, pages 411-416.
Crossref
Crossref
David F.V. Lewis & Brian G. Lake. (1998) Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. Toxicology 125:1, pages 31-44.
Crossref
Crossref